Identification
- Summary
Clobetasol propionate is a corticosteroid used to treat corticosteroid-responsive dermatoses and plaque psoriasis.
- Brand Names
- Clobex, Clodan, Dermovate, Impeklo, Impoyz, Olux, Temovate, Tovet
- Generic Name
- Clobetasol propionate
- DrugBank Accession Number
- DB01013
- Background
Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors.10 It has demonstrated superior activity compared to fluocinonide4 and was first described in the literature in 1974.1
Clobetasol Propionate was granted FDA approval on 27 December 1985.9
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Clobetasol propionate (DB01013)
- Weight
- Average: 466.97
Monoisotopic: 466.192230046 - Chemical Formula
- C25H32ClFO5
- Synonyms
- 21-chloro-9-fluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-propionate
- clobetasol 17-propanoate
- clobetasol 17-propionate
- Clobetasol propionate
- Clobetasol propionate E
- External IDs
- CCI 4725
- CCI-4725
- GR 2/925
- GR-2/925
Pharmacology
- Indication
Clobetasol propionate is indicated to treat moderate to severe plaque psoriasis11,12,13 as well as inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.10,14
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Alopecia Combination Product in combination with: Minoxidil (DB00350), Tretinoin (DB00755) •••••••••••• •••••••• Treatment of Severe plaque psoriasis •••••••••••• •••••••• ••••• ••• Treatment of Severe plaque psoriasis •••••••••••• ••••• Treatment of Severe plaque psoriasis •••••••••••• ••••• Treatment of Corticosteroid responsive, inflammatory dermatosis •••••••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.5 Clobetasol propionate is generally applied twice daily so the duration of action is long.10,11,12,13,14,15 Corticosteroids have a wide therapeutic window as patients may require doses that are multiples of what the body naturally produces.5 Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.5
- Mechanism of action
The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.5 Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.5
Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.5
Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.5 High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.5
Target Actions Organism AGlucocorticoid receptor agonistHumans UAnnexin A1 inducerHumans UMineralocorticoid receptor agonistHumans - Absorption
Twice daily application of clobetasol foam leads to a Cmax of 59±36pg/mL with a Tmax of 5 hours.10 Clobetasol cream showed an increase in clobetasol concentrations from 50.7±96.0pg/mL to 56.3±104.7pg/mL.12
- Volume of distribution
Data regarding the volume of distribution of clobetasole propionate are not readily available.10,11,12,13,14,15
- Protein binding
Data regarding the protein binding of clobetasol propionate are not readily available.10,11,12,13,14,15 Corticosteroids are generally bound to corticosteroid binding globulin6 and serum albumin7 in plasma.
- Metabolism
The metabolism of clobetasol propionate is not well studied but it does induce metabolic enzymes, even when delivered topically.2 The metabolism of clobetasol propionate is predicted to follow similar metabolic pathways to other corticosteroids including the addition of oxygen, hydrogen, glucuronides, and sulfates to form water soluble metabolites.15
- Route of elimination
Corticosteroids are eliminated predominantly in the urine.7
- Half-life
Data regarding the half life of clobetasol propionate are not readily available.3
- Clearance
Data regarding the clearance of clobetasol propionate are not readily available.3
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Data regarding acute overdoses of glucocorticoids are rare.10,11,12 Overdoses of clobetasol propionate can lead to reversible HPA axis suppression and glucocorticoid insufficiency.15 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.8 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.8
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Clobetasol propionate can be increased when it is combined with Abametapir. Abatacept The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be increased when combined with Clobetasol propionate. Acalabrutinib The metabolism of Acalabrutinib can be increased when combined with Clobetasol propionate. Acarbose The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Acarbose. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Clobetasol prodrug ADN79D536H 25122-41-2 FCSHDIVRCWTZOX-DVTGEIKXSA-N - International/Other Brands
- Clobesol (GlaxoSmithKline) / Dermovate (GlaxoSmithKline) / Embeline (Hi-Tech) / Embeline E (Hi-Tech)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Clobetasol Cream 0.05% Cream 0.05 % Topical Prempharm Inc 1996-12-23 2005-08-05 Canada 
Clobetasol Ointment 0.05% Ointment 0.05 % Topical Prempharm Inc 1996-12-23 2005-08-05 Canada Clobetasol Propionate Cream 0.5 mg/1g Topical Stiefel Laboratories, Inc. 2009-12-31 2010-01-01 US 
Clobetasol Propionate Aerosol, foam 0.5 mg/1g Topical Physicians Total Care, Inc. 2011-08-16 Not applicable US Clobetasol Propionate Ointment 0.5 mg/1g Topical Glades Pharmaceuticals LLC 2009-12-31 2010-01-01 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Alti-clobetasol Propionate Cream 0.05% Cream .05 % Topical Altimed Pharma Inc. 1993-12-31 2001-09-05 Canada Alti-clobetasol Propionate Ont 0.05% Ointment .05 % Topical Altimed Pharma Inc. 1993-12-31 2001-09-05 Canada Alti-clobetasol Propionate Scalp Application 0.05% Liquid .05 % Topical Altimed Pharma Inc. 1993-12-31 2001-09-05 Canada Apo-clobetasol Spray Spray 0.05 % w/w Topical Apotex Corporation 2018-07-17 Not applicable Canada Clobetasol Propionate Solution 0.5 mg/1mL Topical Aleor Dermaceuticals Limited 2019-11-02 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image TACOSOL CREAM Cream 0.05 %w/w บริษัท วาย.เอส.พี. (ประเทศไทย) จำกัด 2008-09-18 Not applicable Thailand 
ฮอฟเวท Cream 0.05 %w/w บริษัท โอสถ อินเตอร์ แลบบอราทอรีส์ จำกัด จำกัด 2008-11-20 Not applicable Thailand โคลทาซอล Cream 0.05 %w/w บริษัท บูรพาโอสถ จำกัด จำกัด 2000-12-19 Not applicable Thailand - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Clobeta Clobetasol propionate (0.5 mg/1g) + Coal tar (23 mg/1mL) Kit Topical Tiber Laboratories, LLC 2011-04-06 2012-06-30 US Clobeta Clobetasol propionate (0.5 mg/1g) + Coal tar (23 mg/1mL) Kit Topical Tiber Laboratories, LLC 2011-04-06 2012-06-30 US Clobetair Clobetasol propionate (0.5 mg/1g) + Dimethicone (50 mg/1mL) Kit Topical PureTek Corporation 2020-03-23 2020-05-21 US Clobetavix Clobetasol propionate (0.5 mg/1g) + Clobetasol propionate (0.5 g/1g) Kit Topical Primary Pharmaceuticals, Inc 2019-01-23 Not applicable US Clobetavix Clobetasol propionate (0.5 mg/1g) + Clobetasol propionate (0.5 g/1g) Kit Topical Primary Pharmaceuticals, Inc 2019-01-23 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Calcipotriene 0.005% / Clobetasol Propionate 0.05% Clobetasol propionate (0.05 g/100g) + Calcipotriol (0.005 g/100g) Solution Topical Sincerus Florida, LLC 2019-05-20 Not applicable US Ciclopirox 1% / Clobetasol Propionate 0.05% Clobetasol propionate (0.05 g/100g) + Ciclopirox (1 g/100g) Shampoo Topical Sincerus Florida, LLC 2019-05-01 Not applicable US Ciclopirox Olamine 0.77% / Clobetasol Propionate 0.05% / Salicylic Acid 3%. Clobetasol propionate (0.05 g/100g) + Ciclopirox olamine (1 g/100g) + Salicylic acid (3 g/100g) Shampoo Topical Sincerus Florida, LLC 2019-05-17 Not applicable US Clobetasol Propionate 0.05% / Coal Tar 8% / Salicylic Acid 6% Clobetasol propionate (0.05 g/100g) + Coal tar (8 g/100g) + Salicylic acid (6 g/100g) Cream Topical Sincerus Florida, LLC 2019-05-15 Not applicable US Clobetasol Propionate 0.05% / Levocetirizine Dihydrochloride 2% Clobetasol propionate (0.05 g/100g) + Levocetirizine dihydrochloride (2 g/100g) Shampoo Topical Sincerus Florida, LLC 2019-05-17 Not applicable US
Categories
- Drug Categories
- Adrenal Cortex Hormones
- Anti-Inflammatory Agents
- Corticosteroids
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Inducers
- Cytochrome P-450 CYP3A4 Inducers (strength unknown)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A5 Inducers
- Cytochrome P-450 CYP3A5 Inducers (strength unknown)
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 Substrates
- Fused-Ring Compounds
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hyperglycemia-Associated Agents
- Immunosuppressive Agents
- Pregnadienes
- Pregnadienetriols
- Pregnanes
- Steroids
- Steroids, Fluorinated
- Thyroxine-binding globulin inhibitors
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Pregnane steroids
- Direct Parent
- Gluco/mineralocorticoids, progestogins and derivatives
- Alternative Parents
- Steroid esters / 20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Alpha-acyloxy ketones / Alpha-chloroketones / Fluorohydrins / Cyclic ketones show 10 more
- Substituents
- 11-beta-hydroxysteroid / 11-hydroxysteroid / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 9-halo-steroid / Alcohol / Aliphatic homopolycyclic compound / Alkyl chloride / Alkyl fluoride show 27 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 11beta-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, chlorinated steroid (CHEBI:31414)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 779619577M
- CAS number
- 25122-46-7
- InChI Key
- CBGUOGMQLZIXBE-XGQKBEPLSA-N
- InChI
- InChI=1S/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h8-9,11,14,17-19,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1
- IUPAC Name
- (1R,2S,3aS,3bS,9aS,9bR,10S,11aS)-1-(2-chloroacetyl)-9b-fluoro-10-hydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl propanoate
- SMILES
- [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
References
- Synthesis Reference
Elks, J., Phillipps, G.H. and May, P.J.; US. Patent 3,721,687; March 20, 1973; assigned to Glaxo Laboratories Limited, England.
- General References
- Sparkes CG, Wilson L: The clinical evaluation of a new topical corticosteroid, clobetasol propionate. An international controlled trial. Br J Dermatol. 1974 Feb;90(2):197-203. doi: 10.1111/j.1365-2133.1974.tb06385.x. [Article]
- Finnen MJ, Herdman ML, Shuster S: Induction of drug metabolising enzymes in the skin by topical steroids. J Steroid Biochem. 1984 May;20(5):1169-73. doi: 10.1016/0022-4731(84)90362-5. [Article]
- Hehir M, Du Vivier A, Eilon L, Danie MJ, Shenoy EV: Investigation of the pharmacokinetics of clobetasol propionate and clobetasone butyrate after a single application of ointment. Clin Exp Dermatol. 1983 Mar;8(2):143-51. doi: 10.1111/j.1365-2230.1983.tb01758.x. [Article]
- Jegasothy B, Jacobson C, Levine N, Millikan L, Olsen E, Pinnell S, Cole G, Weinstein G, Porter M: Clobetasol propionate versus fluocinonide creams in psoriasis and eczema. Int J Dermatol. 1985 Sep;24(7):461-5. doi: 10.1111/j.1365-4362.1985.tb05821.x. [Article]
- Yasir M, Sonthalia S: Corticosteroid Adverse Effects . [Article]
- Gardill BR, Vogl MR, Lin HY, Hammond GL, Muller YA: Corticosteroid-binding globulin: structure-function implications from species differences. PLoS One. 2012;7(12):e52759. doi: 10.1371/journal.pone.0052759. Epub 2012 Dec 26. [Article]
- Czock D, Keller F, Rasche FM, Haussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003. [Article]
- Ciriaco M, Ventrice P, Russo G, Scicchitano M, Mazzitello G, Scicchitano F, Russo E: Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S94-8. doi: 10.4103/0976-500X.120975. [Article]
- FDA Approved Drug Products: Temovate Clobetasol Propionate Topical Cream (Discontinued) [Link]
- FDA Approved Drug Products: Olux-E Clobetasol Propionate Topical Aerosol Foam [Link]
- FDA Approved Drug Products: Olux Clobetasol Propionate Topical Aerosol Foam [Link]
- FDA Approved Drug Products: Impoyz Clobetasol Propionate Topical Cream [Link]
- FDA Approved Drug Products: Clobex Clobetasol Propionate Topical Spray [Link]
- FDA Approved Drug Products: Clobex Clobetasol Propionate Topical Lotion [Link]
- Health Canada Approved Drug Products: Clobetasol Propionate Topical Spray [Link]
- External Links
- KEGG Drug
- D01272
- PubChem Compound
- 32798
- PubChem Substance
- 46505670
- ChemSpider
- 30399
- BindingDB
- 39347
- 21245
- ChEBI
- 31414
- ChEMBL
- CHEMBL1159650
- ZINC
- ZINC000003977767
- Therapeutic Targets Database
- DAP001183
- PharmGKB
- PA164744375
- PDBe Ligand
- XRD
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Clobetasol_propionate
- PDB Entries
- 7lad
- FDA label
- Download (95.3 KB)
- MSDS
- Download (74.6 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Alopecia Areata (AA) 1 4 Completed Treatment Chronic Stable Plaque Psoriasis 1 4 Completed Treatment Dermatitis, Chronic 1 4 Completed Treatment Hand Dermatosis 1 4 Completed Treatment Psoriasis 6
Pharmacoeconomics
- Manufacturers
- Perrigo israel pharmaceuticals ltd
- Connetics corp
- Stiefel laboratories inc
- Actavis mid atlantic llc
- E fougera div altana inc
- Taro pharmaceuticals inc
- Teva pharmaceuticals usa
- Altana inc
- Stiefel a gsk co
- Taro pharmaceuticals usa inc
- Hi tech pharmacal co inc
- Perrigo co
- Galderma laboratories l p
- Nycomed us inc
- Galderma laboratories inc
- Tolmar inc
- Wockhardt eu operations (swiss) ag
- Galderma laboratories lp
- Packagers
- Accra Pac Inc.
- Ameri-Pac Inc.
- A-S Medication Solutions LLC
- Contract Pharm
- Dermalogix
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- DPT Laboratories Ltd.
- E. Fougera and Co.
- Galderma Laboratories
- GlaxoSmithKline Inc.
- Glenmark Generics Ltd.
- Hi Tech Pharmacal Co. Inc.
- Inyx Usa Ltd.
- Nycomed Inc.
- Palmetto Pharmaceuticals Inc.
- Perrigo Co.
- Pharma Pac LLC
- Pharmaderm
- Pharmedix
- Physicians Total Care Inc.
- Prasco Labs
- Preferred Pharmaceuticals Inc.
- Quality Care
- Rebel Distributors Corp.
- Stat Rx Usa
- Stiefel Labs
- Taro Pharmaceuticals USA
- Teva Pharmaceutical Industries Ltd.
- Watson Pharmaceuticals
- Wockhardt Ltd.
- Dosage Forms
Form Route Strength Cream Topical .05 % Liquid Topical .05 % Cream Cutaneous Ointment Topical 0.5 mg/g Lotion Topical 0.05 g Lotion Oral 0.05 g Aerosol Topical 0.05 g Solution Oral 0.5 mg/g Ointment Topical 0.44 mg/g Shampoo Topical Aerosol, foam Topical 500 Mikrogramm/g Aerosol, foam Topical 500 UG/G Aerosol, foam Topical 500 mcg/g Emulsion Topical 0.05 g Shampoo Topical 500 MICROGRAMMI/G Emulsion Topical 0.5 mg/g Cream Cutaneous 0.05 g Cream Cutaneous 0.05 % Ointment Cutaneous 0.05 % Ointment Cutaneous 20 G Ointment Topical 20 G Cream 0.05 % Kit Topical Aerosol, foam Topical 0.5 mg/1g Cream Topical .5 mg/1g Cream Topical 0.5 mg/1g Emulsion Topical 0.5 mg/1g Gel Topical .05 mg/1g Gel Topical 0.5 mg/1g Lotion Topical .05 mg/100mL Lotion Topical 0.05 g/100mL Lotion Topical 0.5 mg/1mL Ointment Topical .5 mg/1g Ointment Topical 0.5 mg/1g Shampoo Topical .5 mg/1mL Solution Topical 0.462 mg/1mL Solution Topical 0.5 mg/1mL Spray Topical 0.05 g/1mL Cream Topical Ointment Topical Solution Topical Cream Topical 50 mg Solution Topical 500 mcg/mL Ointment Topical 500 MCG/G Cream Lotion Topical .05 g/100mL Lotion Topical 0.05 mL/100mL Shampoo Topical 0.05 g/100mL Spray Topical 0.5 mg/1mL Shampoo Topical 500 Mikrogramm/g Shampoo Topical 0.05 % Shampoo Topical 0.05 mL/100mL Spray Topical 0.05 % w/w Solution Cutaneous 0.05 % w/w Lotion Cutaneous 0.050 g Solution Cutaneous 0.050 g Ointment Topical 0.05 g Shampoo Topical 0.5 mg/1mL Kit Topical 0.5 mg/1mL Ointment Topical 0.05 % w/w Solution Topical 0.05 %w/v Shampoo Topical Cream Topical 0.05 %w/w Cream Topical 0.05 g/100g Solution Topical 0.4625 mg/1mL Solution Topical 0.5 mg/1g Lotion Topical 50 mg Cream 0.5 mg/g Cream Topical 0.5 mg/g Solution Topical 0.5 mg/g Cream Topical 25 gr Cream Topical 50 gr Ointment Topical 25 gr Ointment Topical 50 gr Lotion Topical 0.05 % Solution Topical .05 % Lotion Topical 0.05 % w/w Cream Topical 0.05 g Cream 0.05 % w/w Gel Topical Shampoo Topical 500 MCG/G Ointment Topical Lotion Topical 0.15 mg/1g Cream Topical 0.25 mg/1g Cream Intravenous 0.05 % Ointment Intravenous 0.05 % Solution Topical Cream Topical Gel Topical 0.05 g Ointment Ointment Topical .05 % Aerosol, foam Topical 0.05 % Aerosol, foam Topical 0.05 % w/w Emulsion Topical 500 MCG/G Cream Cutaneous 0.0500 g Cream Topical 0.05 % Ointment Topical 0.05 % Lotion Topical 25 ml Ointment Cutaneous Cream Topical 0.05 % w/w Shampoo Topical 0.05 % w/w Solution Topical 0.05 % Kit Topical 0.5 mg/1g Capsule Oral 0.050 g Cream Cutaneous 0.050 g Aerosol, foam; kit Topical 0.5 mg/1g Solution Topical 0.05 g Ointment 0.05 %w/w Cream 0.05 %w/w Lotion 0.05 %w/w Ointment Topical 0.05 %w/w - Prices
Unit description Cost Unit Clobex 0.05% Lotion 118ml Bottle 513.56USD bottle Clobex Spray 0.05% Liquid 125ml Bottle 501.7USD bottle Olux 0.05% Foam 100 gm Can 443.77USD can Olux-E 0.05% Foam 100 gm Can 384.32USD can Olux Olux-E Complete Pack 0.05 & 0.05% Miscellaneous 110 gm Can 373.65USD can Clobex 0.05% Shampoo 118ml Bottle 365.67USD bottle Clobetasol Propionate 0.05% Foam 100 gm Can 326.37USD can Clobex 0.05% Lotion 59ml Bottle 280.8USD bottle Clobex Spray 0.05% Liquid 59ml Bottle 278.93USD bottle Olux 0.05% Foam 50 gm Can 239.07USD can Temovate 0.05% Cream 60 gm Tube 234.19USD tube Temovate 0.05% Gel 60 gm Tube 234.19USD tube Temovate E 0.05% Cream 60 gm Tube 234.19USD tube Clobetasol Propionate 0.05% Foam 50 gm Can 177.05USD can Temovate 0.05% Ointment 30 gm Tube 132.55USD tube Temovate 0.05% Solution 50ml Bottle 113.82USD bottle Temovate 0.05% Cream 45 gm Tube 95.43USD tube Clobetasol Propionate 0.05% Gel 60 gm Tube 93.82USD tube Temovate 0.05% Ointment 15 gm Tube 82.1USD tube Clobetasol 17-prop powder 70.74USD g Clobetasol Propionate 0.05% Cream 60 gm Tube 64.15USD tube Clobetasol Propionate 0.05% Ointment 60 gm Tube 64.15USD tube Clobetasol Propionate 0.05% Gel 30 gm Tube 51.66USD tube Clobetasol Propionate 0.05% Ointment 45 gm Tube 50.56USD tube Clobetasol Propionate 0.05% Cream 45 gm Tube 48.57USD tube Temovate 0.05% Gel 15 gm Tube 47.38USD tube Temovate E 0.05% Cream 15 gm Tube 44.9USD tube Clobetasol Propionate 0.05% Solution 50ml Bottle 41.18USD bottle Clobetasol Propionate 0.05% Cream 30 gm Tube 34.79USD tube Clobetasol Propionate 0.05% Ointment 30 gm Tube 34.79USD tube Clobetasol Propionate 0.05% Gel 15 gm Tube 28.86USD tube Clobetasol Propionate 0.05% Solution 25ml Bottle 26.99USD bottle Clobetasol Propionate 0.05% Cream 15 gm Tube 24.94USD tube Clobetasol Propionate 0.05% Ointment 15 gm Tube 24.1USD tube Olux 0.05% foam 6.77USD g Olux-e 0.05% foam 5.9USD g Clobex 0.05% topical lotion 4.58USD ml Temovate emollient 0.05% crm 3.75USD g Olux-olux-e complete pack 3.43USD g Temovate 0.05% cream 3.29USD g Cormax 0.05% cream 2.06USD g Embeline 0.05% cream 1.86USD g Clobetasol 0.05% cream 1.43USD g Dermovate 0.05 % Cream 0.72USD g Dermovate 0.05 % Ointment 0.72USD g Dermovate 0.05 % Lotion 0.63USD g Mylan-Clobetasol 0.05 % Cream 0.38USD g Mylan-Clobetasol 0.05 % Ointment 0.38USD g Novo-Clobetasol 0.05 % Cream 0.38USD g Novo-Clobetasol 0.05 % Ointment 0.38USD g Pms-Clobetasol 0.05 % Cream 0.38USD g Pms-Clobetasol 0.05 % Ointment 0.38USD g Ratio-Clobetasol 0.05 % Cream 0.38USD g Ratio-Clobetasol 0.05 % Ointment 0.38USD g Taro-Clobetasol 0.05 % Cream 0.38USD g Taro-Clobetasol 0.05 % Ointment 0.38USD g Mylan-Clobetasol 0.05 % Lotion 0.33USD g Pms-Clobetasol 0.05 % Lotion 0.33USD g Ratio-Clobetasol 0.05 % Lotion 0.33USD g Taro-Clobetasol 0.05 % Lotion 0.33USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region CA2333869 No 2009-01-06 2019-09-08 Canada CA2333427 No 2007-01-09 2019-06-17 Canada US6126920 No 2000-10-03 2016-03-01 US US8460641 No 2013-06-11 2028-11-05 US US8962000 No 2015-02-24 2025-08-31 US US6730288 No 2004-05-04 2019-09-08 US US7029659 No 2006-04-18 2019-09-08 US US6106848 No 2000-08-22 2017-09-22 US US7700081 No 2010-04-20 2022-01-03 US US8066975 No 2011-11-29 2019-06-17 US US7316810 No 2008-01-08 2019-06-17 US US8066976 No 2011-11-29 2019-06-17 US US5990100 No 1999-11-23 2018-03-24 US US5972920 No 1999-10-26 2018-02-12 US US9855334 No 2018-01-02 2035-03-11 US US9956231 No 2018-05-01 2030-08-31 US US10064875 No 2018-09-04 2030-08-31 US US10588914 No 2020-03-17 2030-08-31 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 196 Health Canada Label logP 3.50 SANGSTER (1994) - Predicted Properties
Property Value Source Water Solubility 0.00413 mg/mL ALOGPS logP 3.49 ALOGPS logP 4.18 Chemaxon logS -5 ALOGPS pKa (Strongest Acidic) 13.63 Chemaxon pKa (Strongest Basic) -3.4 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 80.67 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 119.32 m3·mol-1 Chemaxon Polarizability 48.27 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9814 Caco-2 permeable + 0.812 P-glycoprotein substrate Substrate 0.7852 P-glycoprotein inhibitor I Non-inhibitor 0.7375 P-glycoprotein inhibitor II Non-inhibitor 0.7683 Renal organic cation transporter Non-inhibitor 0.7883 CYP450 2C9 substrate Non-substrate 0.8533 CYP450 2D6 substrate Non-substrate 0.9077 CYP450 3A4 substrate Substrate 0.7967 CYP450 1A2 substrate Non-inhibitor 0.9412 CYP450 2C9 inhibitor Non-inhibitor 0.8713 CYP450 2D6 inhibitor Non-inhibitor 0.8327 CYP450 2C19 inhibitor Non-inhibitor 0.9126 CYP450 3A4 inhibitor Non-inhibitor 0.5411 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9129 Ames test Non AMES toxic 0.8848 Carcinogenicity Non-carcinogens 0.935 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.1435 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9314 hERG inhibition (predictor II) Non-inhibitor 0.5569
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 201.02147 predictedDeepCCS 1.0 (2019) [M+H]+ 202.91689 predictedDeepCCS 1.0 (2019) [M+Na]+ 209.86478 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
- Gene Name
- NR3C1
- Uniprot ID
- P04150
- Uniprot Name
- Glucocorticoid receptor
- Molecular Weight
- 85658.57 Da
References
- Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG: Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med. 2006 Jan;36(1):37-43. Epub 2005 Oct 28. [Article]
- Hofmann TG, Hehner SP, Bacher S, Droge W, Schmitz ML: Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. FEBS Lett. 1998 Dec 28;441(3):441-6. [Article]
- Czock D, Keller F, Rasche FM, Haussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Structural molecule activity
- Specific Function
- Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed:8425544). Play...
- Gene Name
- ANXA1
- Uniprot ID
- P04083
- Uniprot Name
- Annexin A1
- Molecular Weight
- 38713.855 Da
References
- Serres M, Viac J, Comera C, Schmitt D: Expression of annexin I in freshly isolated human epidermal cells and in cultured keratinocytes. Arch Dermatol Res. 1994;286(5):268-72. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
- Gene Name
- NR3C2
- Uniprot ID
- P08235
- Uniprot Name
- Mineralocorticoid receptor
- Molecular Weight
- 107066.575 Da
References
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- SubstrateInducer
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Ahmad N, Mukhtar H: Cytochrome p450: a target for drug development for skin diseases. J Invest Dermatol. 2004 Sep;123(3):417-25. doi: 10.1111/j.0022-202X.2004.23307.x. [Article]
- Usui T, Saitoh Y, Komada F: Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7. doi: 10.1248/bpb.26.510. [Article]
- Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P: Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol. 1992 Jun;41(6):1047-55. [Article]
- Matoulkova P, Pavek P, Maly J, Vlcek J: Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35. doi: 10.1517/17425255.2014.878703. Epub 2014 Jan 23. [Article]
- Olux monograph [File]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]
- Smith G, Ibbotson SH, Comrie MM, Dawe RS, Bryden A, Ferguson J, Wolf CR: Regulation of cutaneous drug-metabolizing enzymes and cytoprotective gene expression by topical drugs in human skin in vivo. Br J Dermatol. 2006 Aug;155(2):275-81. [Article]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Binder
- General Function
- Steroid binding
- Specific Function
- Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
- Gene Name
- SERPINA6
- Uniprot ID
- P08185
- Uniprot Name
- Corticosteroid-binding globulin
- Molecular Weight
- 45140.49 Da
References
- Gardill BR, Vogl MR, Lin HY, Hammond GL, Muller YA: Corticosteroid-binding globulin: structure-function implications from species differences. PLoS One. 2012;7(12):e52759. doi: 10.1371/journal.pone.0052759. Epub 2012 Dec 26. [Article]
- Schimmer B, Funder J (2018). 46. In Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education. [ISBN:978-1-25-958473-2]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Binder
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Czock D, Keller F, Rasche FM, Haussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003. [Article]
- Schimmer B, Funder J (2018). 46. In Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education. [ISBN:978-1-25-958473-2]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55